{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:58:17Z","timestamp":1793656697580,"version":"4.5.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jacc.2025.03.009","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T11:38:01Z","timestamp":1743593881000},"page":"1721-1735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Interplay of Chronic Kidney Disease and\u00a0the Effects of Tirzepatide in Patients With Heart\u00a0Failure, Preserved Ejection\u00a0Fraction, and Obesity"],"prefix":"10.1016","volume":"85","author":[{"given":"Milton","family":"Packer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Zile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5020-7912","authenticated-orcid":false,"given":"Yang","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.03.009_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCHEARTFAILURE.112.972828","article-title":"Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction","volume":"6","author":"Ho","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","article-title":"The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF","volume":"6","author":"Savji","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.009_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/20543581241293199","article-title":"Prevalence, characteristics, and outcomes of people with a high body mass index across the kidney disease spectrum: a population-based cohort study","author":"Sahi","year":"2024","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.jacc.2025.03.009_bib5","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.kint.2016.12.013","article-title":"A\u00a0systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population","volume":"91","author":"Garofalo","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2025.03.009_bib6","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrneph.2016.75","article-title":"Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis","volume":"12","author":"D'Agati","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacc.2025.03.009_bib7","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.2337\/db20-1031","article-title":"Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes","volume":"70","author":"Chen","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.03.009_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.707126","article-title":"Perirenal adipose tissue inflammation: novel insights linking metabolic dysfunction to renal diseases","volume":"12","author":"Hammoud","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.03.009_bib9","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/cvr\/cvaa336","article-title":"Obesity, kidney dysfunction, and inflammation: interactions in hypertension","volume":"117","author":"Hall","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.03.009_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: mechanistic links","volume":"15","author":"Hall","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacc.2025.03.009_bib11","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.009_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ejhf.1167","article-title":"Derangements in adrenergic-adipokine signalling establish a neurohormonal basis for obesity-related heart failure with a preserved ejection fraction","volume":"20","author":"Packer","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ijcard.2016.11.194","article-title":"HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin","volume":"228","author":"Fax\u00e9n","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2337\/db23-0444","article-title":"Genetic analysis of obesity-induced diabetic nephropathy in BTBR mice","volume":"73","author":"Keller","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.jacc.2025.03.009_bib15","doi-asserted-by":"crossref","first-page":"F793","DOI":"10.1152\/ajprenal.00590.2015","article-title":"Early development of podocyte injury independently of hyperglycemia and elevations in arterial pressure in nondiabetic obese Dahl SS leptin receptor mutant rats","volume":"311","author":"McPherson","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/HJH.0000000000000526","article-title":"Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase in mid-regional pro-atrial natriuretic peptide in morbid obese patients","volume":"33","author":"Bonfils","year":"2015","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.jacc.2025.03.009_bib17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1381\/0960892053923734","article-title":"Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis","volume":"15","author":"Ruano","year":"2005","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2025.03.009_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11695-022-06444-8","article-title":"Change in adipokines and gastrointestinal hormones after bariatric surgery: a meta-analysis","volume":"33","author":"Huang","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.jacc.2025.03.009_bib19","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/ckj\/sfaa266","article-title":"Renoprotective role of bariatric surgery in patients with established chronic kidney disease","volume":"14","author":"Morales","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jacc.2025.03.009_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.kint.2016.02.039","article-title":"Bariatric surgery is associated with improvement in kidney outcomes","volume":"90","author":"Chang","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2025.03.009_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1386542","article-title":"Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus","volume":"15","author":"Rodr\u00edguez Jim\u00e9nez","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jacc.2025.03.009_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbf.3751","article-title":"Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice","volume":"40","author":"Martins","year":"2022","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.jacc.2025.03.009_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","article-title":"STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2025.03.009_bib24","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1111\/dom.15820","article-title":"The dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice","volume":"26","author":"Reis-Barbosa","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.03.009_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.03.009_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bbrc.2023.04.012","article-title":"GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning","volume":"664","author":"Wang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacc.2025.03.009_bib27","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.orcp.2019.03.003","article-title":"Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-alpha-mediated NF-kappaB and MAPK pathway","volume":"13","author":"Ye","year":"2019","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.jacc.2025.03.009_bib28","doi-asserted-by":"crossref","first-page":"F181","DOI":"10.1152\/ajprenal.00302.2017","article-title":"Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes","volume":"314","author":"Guo","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2025.03.009_bib30","doi-asserted-by":"crossref","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","article-title":"Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus","volume":"316","author":"Tonneijck","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib31","doi-asserted-by":"crossref","first-page":"F137","DOI":"10.1152\/ajprenal.00064.2012","article-title":"Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat","volume":"304","author":"Thomson","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib32","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.009_bib33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/ndt\/gfae150","article-title":"Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6","volume":"40","author":"Apperloo","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.03.009_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.009_bib35","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1161\/01.CIR.74.4.766","article-title":"Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system","volume":"74","author":"Packer","year":"1986","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.jacc.2025.03.009_bib36","article-title":"Role of renal sympathetic nerves in GLP-1 (glucagon-like peptide-1) receptor agonist exendin-4-mediated diuresis and natriuresis in diet-induced obese rats","volume":"10","author":"Liu","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jacc.2025.03.009_bib37","article-title":"Early renal denervation attenuates cardiac dysfunction in heart failure with preserved ejection fraction","volume":"13","author":"Doiron","year":"2024","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.03.009_bib38","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.jacc.2017.08.056","article-title":"Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney","volume":"70","author":"Polhemus","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/MNH.0000000000000583","article-title":"Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how?","volume":"29","author":"Kassem","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jacc.2025.03.009_bib40","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1159\/000493657","article-title":"Kidney response to heart failure: proteomic analysis of cardiorenal syndrome","volume":"43","author":"Melenovsky","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.jacc.2025.03.009_bib41","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.124.071110","article-title":"Therapeutic effects of heart failure medical therapies on standardized kidney outcomes: comprehensive individual participant-level analysis of 6 randomized clinical trials","volume":"150","author":"Butt","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.009_bib42","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.009_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2019.05.010","article-title":"Trends in kidney function outcomes following RAAS inhibition in patients with heart failure with reduced ejection fraction","volume":"75","author":"McCallum","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2025.03.009_bib44","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.jacc.2020.12.057","article-title":"Spironolactone in patients with heart failure, preserved ejection fraction, and worsening renal function","volume":"77","author":"Beldhuis","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib45","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.jacc.2024.08.034","article-title":"Why has it been challenging to modify kidney disease progression in patients with heart failure?","volume":"84","author":"Vaduganathan","year":"2024","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib46","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/eurheartj\/ehad158","article-title":"Drugs that slow the progression of diabetic kidney disease: are renoprotective effects attenuated in heart failure?","volume":"44","author":"Packer","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.03.009_bib47","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.009_bib48","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2025.03.009_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2024.10.448","article-title":"GLP-1 receptor agonist in nonobese patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction","author":"Khadke","year":"2024","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib50","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.009_bib51","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jacc.2025.03.009_bib52","doi-asserted-by":"crossref","DOI":"10.1097\/j.pbj.0000000000000233","article-title":"Chronic kidney disease prevalence in asymptomatic patients with risk factors-usefulness of serum cystatin C: a cross-sectional study","volume":"8","author":"Avila","year":"2023","journal-title":"Porto Biomed J"},{"key":"10.1016\/j.jacc.2025.03.009_bib53","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.xkme.2020.08.008","article-title":"Performance of glomerular filtration rate estimating equations before and after bariatric surgery","volume":"2","author":"Chang","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.jacc.2025.03.009_bib54","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/oby.22574","article-title":"Estimated glomerular filtration rate bias in participants with severe obesity regardless of deindexation","volume":"27","author":"Guebre-Egziabher","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2025.03.009_bib55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2478\/ams-2013-0020","article-title":"Creatinine or cystatin C - which is a better index of renal function in morbid obesity?","volume":"58","author":"Mysliwiec","year":"2013","journal-title":"Adv Med Sci"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.009_bib56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12882-017-0474-0","article-title":"Effect of large weight reductions on measured and estimated kidney function","volume":"18","author":"von Scholten","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jacc.2025.03.009_bib57","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","article-title":"Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)","volume":"21","author":"Tuttle","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.03.009_bib58","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/oby.2009.96","article-title":"Potential contribution of adipose tissue to elevated serum cystatin C in human obesity","volume":"17","author":"Naour","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jacc.2025.03.009_bib59","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/ki.2008.638","article-title":"Factors other than glomerular filtration rate affect serum cystatin C levels","volume":"75","author":"Stevens","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2025.03.009_bib60","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clnesp.2022.07.010","article-title":"Relationship between the creatinine\/cystatin C ratio and muscle mass measured by CT-scan in cancer patients","volume":"51","author":"Tlemsani","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.jacc.2025.03.009_bib61","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of tirzepatide on the clinical trajectory of patients with heart failure, a preserved ejection fraction, and obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.03.009_bib62","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.mayocp.2023.07.008","article-title":"Obesity, cardiorenal comorbidities, and risk of hospitalization in patients with heart failure with preserved ejection fraction","volume":"98","author":"Morgen","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.009_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2024.151516","article-title":"Epidemiology and management of patients with kidney disease and heart failure with preserved ejection fraction","volume":"44","author":"Tuttle","year":"2024","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.jacc.2025.03.009_bib64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ejhf.1377","article-title":"The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacc.2025.03.009_bib65","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12933-023-01899-0","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction","volume":"22","author":"Kintscher","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.03.009_bib66","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ndt\/gfx081","article-title":"Obesity modulates the association between systolic blood pressure and albuminuria","volume":"33","author":"Fotheringham","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.03.009_bib67","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib68","first-page":"8085","article-title":"Association of rise in C-reactive protein with decline in renal function following partial nephrectomy","volume":"22","author":"Cohen","year":"2015","journal-title":"Can J Urol"},{"key":"10.1016\/j.jacc.2025.03.009_bib69","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1093\/ndt\/gfr081","article-title":"Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes","volume":"26","author":"Yilmaz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2025.03.009_bib70","doi-asserted-by":"crossref","first-page":"H260","DOI":"10.1152\/ajpheart.00449.2024","article-title":"A\u00a0minimally invasive swine model of chronic kidney disease-associated heart failure","volume":"328","author":"Mavropoulos","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib71","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jchf.2023.01.029","article-title":"Chronic kidney disease, heart failure, and adverse cardiac remodeling in older adults: the ARIC study","volume":"11","author":"Buckley","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000349968","article-title":"Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI)","volume":"182","author":"Cruz","year":"2013","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.jacc.2025.03.009_bib73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cardfail.2019.09.015","article-title":"Adverse renal response to decongestion in the\u00a0obese phenotype of heart failure with preserved ejection fraction","volume":"26","author":"Reddy","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib74","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-106-3-346","article-title":"Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure","volume":"106","author":"Packer","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2025.03.009_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.03.009_bib76","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/ejhf.3304","article-title":"Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril\/valsartan in PARAGON-HF","volume":"26","author":"Lassen","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib77","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ki.2014.112","article-title":"The body composition and excretory burden of lean, obese, and severely obese individuals has implications for the assessment of chronic kidney disease","volume":"86","author":"Fotheringham","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2025.03.009_bib78","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cardfail.2020.01.003","article-title":"Renal dysfunction in heart failure with preserved ejection fraction: insights from the RELAX trial","volume":"26","author":"Patel","year":"2020","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib79","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/ejhf.2857","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial","volume":"25","author":"Sharma","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib80","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"Mc Causland","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib82","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1159\/000502874","article-title":"Association of chronic kidney disease with preserved ejection fraction heart failure is independent of baseline cardiac function","volume":"44","author":"Mavrakanas","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.jacc.2025.03.009_bib83","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/ejhf.821","article-title":"Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"19","author":"L\u00f6fman","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.03.009_bib84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/IJNRD.S196976","article-title":"Evaluation of discriminative capacity of two formulas of CKD-EPI to predict complications after the first episode of heart failure with preserved ejection fraction","volume":"12","author":"Shchekochikhin","year":"2019","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.jacc.2025.03.009_bib85","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacc.2025.03.009_bib86","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","article-title":"Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial","volume":"85","author":"Mc Causland","year":"2025","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.03.009_bib87","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/dom.14410","article-title":"Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial","volume":"23","author":"van Ruiten","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2025.03.009_bib88","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jacc.2025.03.009_bib89","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725053409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725053409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T23:58:15Z","timestamp":1749859095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725053409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":89,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0735109725053409"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.009","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interplay of Chronic Kidney Disease and\u00a0the Effects of Tirzepatide in Patients With Heart\u00a0Failure, Preserved Ejection\u00a0Fraction, and Obesity","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}